Psychopharmacological challenge studies in psychiatric research

References

• ANGRIST, B. & GERSHON, E. (1970). The phenomenology of experimentally induced amphetamine psychosis preliminary observations. Biological Psychiatry, 2, 95 107.
   Google Scholar
• ANGRIST, B., PESELOW, E., RUBENSTEIN, M., WOLKIN, A. & ROTROSEN, J. (1985). Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology, 78, 128 130.
   Google Scholar
• ANGRIST, B., ROTROSEN, J. & GERSHON, S. (1980). Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology, 72, 17 19.
   Google Scholar
• BELL, D.S. (1973). The experimental production of amphetamine psychosis. Archives of General Psychiatry, 29, 35 40.
   Google Scholar
• BUNNEY, W. & DAVIS, J. (1965). Norepinephrine in depressive reactions: a review. Archives of General Psychiatry, 13, 483 494.
   Google Scholar
• CARLSSON, A. & LINDQUIST, M. (1964). Effects of chlorpromazine or haloperidol formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacology Toxicity, 20, 140 144.
   Google Scholar
• CHARNEY, D.S., HENINGER, G.R. & BREIER, A. (1984). Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry, 41(8), 751 763.
   Google Scholar
• CONNELL, P.H. (1958). Amphetamine psychoses. Maudsley, Monographs No. 5. London: Oxford University Press.
   Google Scholar
• COPPEN, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113, 1237 1264.
   Google Scholar
• CORSSEN, G. & DOMINO, E.F. (1966). Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesthesia and Analgesia, 45(1), 29 40.
   Google Scholar
• DAVIS, J.M. & ANDRIUKAITIS, S. (1986). The natural course of schizophrenia and effective maintenance drug treatment. Journal of Clinical Psychopharmacology, 6(1 Suppl.), 2S 10S.
   Google Scholar
• DELAY, J. & DENIKER, P. (1952). 38 case de psychoses traitees par la cure prolongee et continue de 4560 RP. C.R. 50e congres des alienistes et neurologie de Langue Fse, 503 513.
   Google Scholar
• D’SOUZA, D.C., BERMAN, R.M., KRYSTAL, J.H. & CHARNEY, D.S. (1999). Symptom provocation studies in psychiatric disorders: scientific value, risks and future. Biological Psychiatry, 46, 1060 1080.
   Google Scholar
• FREEDMAN, D.X. (1961). Studies of LSD-25 and serotonin in the brain. Proceedings of the Third World Congress of Psychiatry, 1, 653 658.
   Google Scholar
• GRIFFITH, J.D. & OATES, J. (1968). Paranoid episodes induced by drug: schizophrenia model? Journal of the American Medical Association, 205(11), 39 40.
   Google Scholar
• GRIFFITH, J.D., CAVANAUGH, J., HELD, J. & OATES, J. (1970). Experimental psychosis induced by the administration of d-amphetamine. In COSTA & GARATTINI (Eds), Amphetamines and related compounds: proceedings of the Mario Negri Institute for Pharmacological Research (pp. 897 905). New York: Raven Press.
   Google Scholar
• GRIFFITH, J.D., CAVANAUGH, J., HELD, J. & OATES, J. (1972). Dextroamphetamine evaluation of psychomimetic properties in man. Archives of General Psychiatry, 26, 17 100.
   Google Scholar
• HOPE, J.M., CALLAWAY, E. & SANDS, S.L. (1951). Intravenous pervitin and the psychopathology of schizophrenia. Diseases of the Nervous System, 12, 67 72.
   Google Scholar
• HORNYKIEWICZ, O. (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacology Review, 18(2), 925 964.
   Google Scholar
• JANOWSKY, D.S., EL-YOUSEF, M.K., DAVIS, J.M. & SEKERKE, H.J. (1973). Provocation of schizophrenic symptoms by intravenous administration of methylphernidate. Archives of General Psychiatry, 28, 185 191.
   Google Scholar
• KRYSTAL, J.H., KARPER, L.P., SEIBYL, J.S. et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychomimetic, perceptual, cognitive and neuroendocrine responses. Archives of General Psychiatry, 51, 199 214.
   Google Scholar
• KRYSTAL, J.H., D’SOUZA, D.C., BELGER, A., ANAND, A., CHARNEY, D.S., AGHAJANIAN, G.K. & MOGHADDAM, B. (1999). Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology, 22, S143 S157.
   Google Scholar
• KRYSTAL, J., BELGER, A., ABI-SAAB, W., MOGHADDAM, B., CHARNEY, D.S., ANAND, A., MADONICK, S. & D’SOUZA, D.C. (2000). Glutamatergic contributions to cognitive dysfunction in schizophrenia. In: T. SHARMA & P. HARVEY (Eds), Cognitive functioning in schizophrenia. Oxford: Oxford University Press.
   Google Scholar
• LAHTI, A., HOLCOMB, H.H., MEDOFF, D.R. & TAMMINGA, C.A. (1995a). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport, 6, 869 872.
   Google Scholar
• LAHTI, A.C., KOFFEL, B., LAPORTE, D. & TAMMINGA, C.A. (1995b). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13, 9 19.
   Google Scholar
• LAPIN, I.P. & OXENKRUG, G.F. (1969). Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet, 1, 132 136.
   Google Scholar
• LARUELLE, M. ABIDARGHAM, A., VAN DYKE, C., GIL, R., D’SOUZA, D.C., et al. (1996). Increased synaptic dopamine release in drug free schizophrenic subjects. Proceedings of the National Academy of Sciences USA, 93, 9235 9240.
   Google Scholar
• LEIBERMAN, J.A., KINON, B.J. & LOEBEL, A.D. (1990). Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin, 16, 97 110.
   Google Scholar
• LIEBERMAN, J.A., KANE, J.M., GADALETA, D., BRENNER, R., LESSER, M.S. & KINON, B. (1984). Methylphenidate challenge as a predictor of relapse in schizophrenia. American Journal of Psychiatry, 141(5), 633 638.
   Google Scholar
• LIEBERMAN, J.A., KANE, J.M., ALVIR, J. (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology, 91, 415 433.
   Google Scholar
• LUBY, E.D., GOTTLIEB, J.S., COHEN, B.D., ROSENBAUM, G. & DOMINO, E.F. (1959). Model psychoses and schizophrenia. American Journal of Psychiatry, 119, 61 67.
   Google Scholar
• MALHOTRA, A.K., PINALS, D.A., WEINGARTEN, H., SIROCCO, K., MISAR, C.D., PICKAR, D. & BREIER, A. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14, 301 307.
   Google Scholar
• PENNES, H.H. (1954). Clinical reactions of schizophrenics to intravenous amytal, pervitin hydrochloride, mescaline sulfate, and D-lysergic acid diethylamide (LSD). Journal of Nervous and Mental Disease, 119, 95 112.
   Google Scholar
• RANDRUP, A. & MUNKVAD, I. (1970). Biochemical, anatomical and psychological investigation of stereotyped behavior induced by amphetamines. In: COSTA & GARATTINI (Eds), Amphetamines and related compounds (pp. 695 715). New York: Raven Press.
   Google Scholar
• SCHILDKRAUT, J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122, 509 521.
   Google Scholar
• SIMON, S.L. & TRAUBE, H. (1946). A preliminary study on the use of methidrine in psychiatric diagnosis. Journal of Nervous and Mental Disease, 104, 593 596.
   Google Scholar
• VAN KAMMEN, D.P., BUNNEY, W.E., DOCHERTY, J.P., MARDER, S.R., EBERT, M.H., ROSENBLATT, J.E. & RAYNER, J.N. (1982a). D-Amphetamine-induced heterogenous changes in psychotic behavior in schizophrenia. American Journal of Psychiatry, 139, 991 997.
   Google Scholar
• VAN KAMMEN, D.P., DOCHERTY, J.P., MARDER, S.R., SCHULZ, S.C., DALTON, I., BUNNEY, JR, W.E. (1982b). Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response. Archives of General Psychiatry, 39(3), 261 6.
   Google Scholar
• ZUKIN, S.R. & ZUKIN, R.S. (1980). (3H)-Phencyclidine binding to specific brain receptor sites. Psychopharmacology Bulletin, 16(4), 59 62.
   Google Scholar